Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
raludotatug deruxtecan
- Development stage
- Phase 3
- Lead developer
- Daiichi Sankyo
- Modality
- Cytotoxic ADCs → Antibody-Drug Conjugates (ADCs) → Antibody Conjugates → Antibody-Based Therapeutics, Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules
- Administration
- Intravenous
01
Overview
Raludotatug deruxtecan is an investigational antibody-drug conjugate (ADC) specifically engineered to target cadherin-6 (CDH6), a tumor-associated antigen highly expressed in several cancer types, including ovarian and renal cell carcinoma. The drug consists of a humanized anti-CDH6 IgG1 monoclonal antibody linked via tetrapeptide-based cleavable linkers to multiple molecules of DXd, a potent DNA topoisomerase I inhibitor payload derived from exatecan. Upon binding to CDH6 on the surface of cancer cells, the ADC is internalized and trafficked to lysosomes where the cytotoxic payload is released. This results in inhibition of cell replication and induction of apoptosis; additionally, the membrane-permeable DXd can exert bystander effects on neighboring tumor cells with heterogeneous CDH6 expression. Raludotatug deruxtecan has demonstrated strong antitumor activity in preclinical models and is currently being evaluated in clinical trials for advanced ovarian cancer. It is being developed by Daiichi Sankyo and Merck and utilizes proprietary DXd ADC technology developed by Daiichi Sankyo. It remains investigational as of April 2025.
- Other names
- raludotatug deruxtecan
02
Targets
CDH6 (Cadherin-6)
Beyond the preview
Go deeper on raludotatug deruxtecan.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on raludotatug deruxtecan.